Treatment
autoimmune disease
AUTOIMMUNE DISEASE
Eligible participants received caplacizumab 10 mg once daily, in addition to standard care, throughout the TPE treatment period and for 30 days after completion of TPE. The first caplacizumab dose was administered by intravenous injection at least 15 min prior to TPE, with subsequent doses administered subcutaneously after TPE. After Day 2, caplacizumab was administered subcutaneously after TPE. Standard care was administered according to Japanese guidelines [The minimum study period was the duration of daily TPE treatment plus 30 days of post-TPE treatment, and 30 days of follow-up period, but this could be extended if participants did not have resolution of the underlying autoimmune disease (Fig. Study design. 